Previous 10 | Next 10 |
-- Substantial Treatment Effect Observed in Patients with Enteric Hyperoxaluria, Including Robust Reductions in Both Urine and Plasma Oxalate – -- Reloxaliase Well-Tolerated Over 12 Weeks of Dosing -- -- Detailed Results to be Presented at OHF International Hyperoxaluria Worksho...
NEWTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, to...
Gainers: Soliton (NASDAQ: SOLY ) +124% . Exela Technologies (NASDAQ: XELA ) +33% . Flexible Solutions International (NYSEMKT: FSI ) +24% . IMAC Holdings (NASDAQ: IMAC ) +20% . Biocept (NASDAQ: BIOC ) +21% . Anaplan (NYSE: PLAN ) +18% . MYnd Analytics (NASDAQ: MYND ) +18% . Sea...
Allena Pharmaceuticals (NASDAQ: ALNA ): Q1 GAAP EPS of -$0.55 misses by $0.06 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Entered into Agreement with Duke Clinical Research Institute (DCRI) to Support Phase 3 URIROX-2™ Trial and Promote Enteric Hyperoxaluria Disease Awareness – -- All Clinical Programs Progressing on Track; Expect to Report Initial Data from Study 206 in Second Quarter a...
NEWTON, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
Allena Pharmaceuticals ( ALNA ) is a micro-cap targeting a very specific niche indication called Hyperoxaluria, a metabolic disorder characterized by significantly elevated oxalate levels in the urine. Its entire pipeline is centered around various forms of this disease. Its lead drug candidat...
NEWTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this Read more ...
Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.46. More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Allena Pharmaceuticals Inc. Company Name:
ALNA Stock Symbol:
NASDAQ Market:
Allena Pharmaceuticals Inc. Website:
Buying Penny Stocks on July 29th? Here’s What You Need to Know If you’re looking for the best penny stocks to buy right now, there are hundreds of options to choose from. As a result, it all comes down to finding the best penny stocks that fit your trading strateg...
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme the...
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...